Clinical Trial Update: BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCL [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing BEAM conditioning with autologous stem cell transplant to BEAM with Zevalin in relapsed or refractory diffuse large B-cell lymphoma wa…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• BEAM conditioning regimen
• Zevalin (ibritumomab tiuxetan)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Status: TERMINATED | Results posted: 2018-02-13